Indaptus Therapeutics, Inc. (INDP) has 10 open-market insider trades by 5 insiders since 2021. The most active filer is Jeffrey A. Meckler, CEO & Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Glen R. Anderson | 10% Owner | — | 1 | $433K | 2023-08-14 |
| Jeffrey A. Meckler | CEODir | — | 6 | $391K | 2025-12-22 |
| Michael James Newman | CSODir | — | 1 | $71K | 2025-12-22 |
| Boyan Vesselinov Litchev | Chief Medical Officer | — | 1 | $3K | 2022-12-01 |
| Walt Addison Linscott | COO | — | 1 | $393 | 2025-12-22 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Glen R. Anderson | 10% Owner | Buy | $433K | 2023-08-10 |
| Jeffrey A. Meckler | Director | Buy | $19K | 2022-11-18 |
| Jeffrey A. Meckler | Director | Buy | $29K | 2022-09-08 |
| Walt Addison Linscott | Chief Business Officer | Buy | $393 | 2022-09-07 |
| Jeffrey A. Meckler | Director | Buy | $25K | 2022-09-06 |
| Jeffrey A. Meckler | CEO & Director | Buy | $104K |
Companies that share insiders with INDP, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2022-06-06 |
| Boyan Vesselinov Litchev | Chief Medical Officer | Buy | $3K | 2022-01-31 |
| Michael James Newman | CSO & Director | Sell | $100K | 2022-01-31 |
| Jeffrey A. Meckler | CEO & Director | Buy | $130K | 2021-11-18 |
| Jeffrey A. Meckler | CEO & Director | Buy | $84K | 2021-09-14 |